3B BlackBio Dx Ltd. Achieves Significant Growth in Molecular Diagnostics Amid Global Challenges, Proposes Dividend of 4%

3B BlackBio Dx Ltd., an ISO 13485:2016 certified company, has reported strong financial performance in the fiscal year 2024-2025. The company's revenue from operations stands at Rs. 8,428.25 lakh, with an EBITDA of Rs. 4,787.55 lakh. The company has strengthened its leadership in molecular diagnostics, with its TRUPCR® portfolio present in over 70 countries. A significant achievement is the acquisition of Coris BioConcept SRL, Belgium, which will broaden the product range and accelerate access to global markets. The Board has proposed a dividend of 4% per equity share, pending shareholder approval.